Access denied

You are not authorized to access this page.
Project
Sponsor Location(s) Topics Start End
A Phase 2 Multicenter, Single Dose, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination with Phototherapy in Neonates United States Newborn and Infant Health
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection Gilead Sciences, Inc. United States Infectious Disease
A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination with Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus Vertex Pharmaceuticals, Inc. United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment, Pediatrics
Childhood Liver Disease Research and Education Network (ChiLDREN) - UCSF (CC) NIH National Institute of Diabetes and Digestive and Kidney Diseases United States Pediatrics
Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection Gilead Sciences, Inc. United States Pediatrics
Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infection Gilead Sciences, Inc. United States Infectious Disease, Pharmacology and Drug Treatment
Protocol AI463-189-004: A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) Bristol-Myers Squibb Company China; South Korea; India; Israel; Poland; Romania; Russia; United Kingdom HIV/AIDS, Pharmacology and Drug Treatment
YV25718: A phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, Ro 25-8310) compared to untreated control in children with HBeAg positive chronic hepatitis B Genentech, Inc. United States Infectious Disease, Pediatrics